Hypereosinophilic Syndrome
A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.
Subtype terms (1)
More specific conditions that are subtypes of Hypereosinophilic Syndrome in the MeSH hierarchy.
- Pulmonary Eosinophilia
5 drugs (4 approved, 1 experimental)
Drugs by status
Approved for this indication (2)
Phase 4 trials (1)
Phase 3 trials (2)
Phase 2 trials (6)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (4)
Organization Involved with Phase 2 Indications (14)
- Incyte
- Bristol-Myers Squibb
- Knopp Biosciences
- Case Western Reserve University
- University of Washington
- Johns Hopkins University
- Northern Italy Leukemia Group
- Southwest Oncology Group
- Stanford University
- Thomas Jefferson University
- University of Milan
- University of Bologna
- University of Cincinnati
- University of Texas at Houston